QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.059527v1 309/2/661    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gougat, J. Articles by Le Fur, G. Search for Related Content PubMed PubMed Citation Articles by Gougat, J. Articles by Le Fur, G.

INFLAMMATION AND IMMUNOPHARMACOLOGY

SSR240612 [(2R)-2-[((3R)-3-(1,3-Benzodioxol-5-yl)-3-{[(6-methoxy-2-naphthyl)sulfonyl]amino}propanoyl)amino]-3-(4-{[2R,6S)-2,6-dimethylpiperidinyl]methyl}phenyl)-N-isopropyl-N-methylpropanamide Hydrochloride], a New Nonpeptide Antagonist of the Bradykinin B₁ Receptor: Biochemical and Pharmacological Characterization

Sanofi-Synthelabo Recherche, Montpellier, France

The biochemical and pharmacological properties of a novel non-peptide antagonist of the bradykinin (BK) B₁ receptor, SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-{[(6-methoxy-2-naphthyl)sulfonyl]amino}propanoyl)amino]-3-(4-{[2R,6S)-2,6-dimethylpiperidinyl]methyl}phenyl)-N-isopropyl-N-methylpropanamide hydrochloride] were evaluated. SSR240612 inhibited the binding of [³H]Lys⁰-des-Arg⁹-BK to the B₁ receptor in human fibroblast MRC5 and to recombinant human B₁ receptor expressed in human embryonic kidney cells with inhibition constants (K_i) of 0.48 and 0.73 nM, respectively. The compound selectivity for B₁ versus B₂ receptors was in the range of 500- to 1000-fold. SSR240612 inhibited Lys⁰-desAr⁹-BK (10 nM)-induced inositol monophosphate formation in human fibroblast MRC5, with an IC₅₀ of 1.9 nM. It also antagonized des-Arg⁹-BK-induced contractions of isolated rabbit aorta and mesenteric plexus of rat ileum with a pA₂ of 8.9 and 9.4, respectively. Antagonistic properties of SSR240612 were also demonstrated in vivo. SSR240612 inhibited des-Arg⁹-BK-induced paw edema in mice (3 and 10 mg/kg p.o. and 0.3 and 1 mg/kg i.p.). Moreover, SSR240612 reduced capsaicin-induced ear edema in mice (0.3, 3 and 30 mg/kg p.o.) and tissue destruction and neutrophil accumulation in the rat intestine following splanchnic artery occlusion/reperfusion (0.3 mg/kg i.v.). The compound also inhibited thermal hyperalgesia induced by UV irradiation (1 and 3 mg/kg p.o.) and the late phase of nociceptive response to formalin in rats (10 and 30 mg/kg p.o.). Finally, SSR240612 (20 and 30 mg/kg p.o.) prevented neuropathic thermal pain induced by sciatic nerve constriction in the rat. In conclusion, SSR240612 is a new, potent, and orally active specific non-peptide bradykinin B₁ receptor antagonist.

Address correspondence to: Jean Gougat, Sanofi-Synthelabo Recherche, 371 rue du Prof. J. Blayac, Cedex 04, 34184 Montpellier, France. E-mail: jean.gougat{at}sanofi-synthelabo.com

This article has been cited by other articles:

				J. Klein, J. Gonzalez, J. Duchene, L. Esposito, J. P. Pradere, E. Neau, C. Delage, D. Calise, A. Ahluwalia, P. Carayon, et al. Delayed blockade of the kinin B1 receptor reduces renal inflammation and fibrosis in obstructive nephropathy FASEB J, January 1, 2009; 23(1): 134 - 142. [Abstract] [Full Text] [PDF]

				N. L. M. Quintao, G. F. Passos, R. Medeiros, A. F. Paszcuk, F. L. Motta, J. B. Pesquero, M. M. Campos, and J. B. Calixto Neuropathic Pain-Like Behavior after Brachial Plexus Avulsion in Mice: The Relevance of Kinin B1 and B2 Receptors J. Neurosci., March 12, 2008; 28(11): 2856 - 2863. [Abstract] [Full Text] [PDF]

				J. Duchene, F. Lecomte, S. Ahmed, C. Cayla, J. Pesquero, M. Bader, M. Perretti, and A. Ahluwalia A Novel Inflammatory Pathway Involved in Leukocyte Recruitment: Role for the Kinin B1 Receptor and the Chemokine CXCL5 J. Immunol., October 1, 2007; 179(7): 4849 - 4856. [Abstract] [Full Text] [PDF]

				J. E. Hawkinson, B. G. Szoke, A. W. Garofalo, D. S. Hom, H. Zhang, M. Dreyer, J. Y. Fukuda, L. Chen, B. Samant, S. Simmonds, et al. Pharmacological, Pharmacokinetic, and Primate Analgesic Efficacy Profile of the Novel Bradykinin B1 Receptor Antagonist ELN441958 J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 619 - 630. [Abstract] [Full Text] [PDF]

				F. Porreca, T. W. Vanderah, W. Guo, M. Barth, P. Dodey, V. Peyrou, J. M. Luccarini, J.-L. Junien, and D. Pruneau J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 195 - 205. [Abstract] [Full Text] [PDF]

				N. Picard, M. Van Abel, C. Campone, M. Seiler, M. Bloch-Faure, J. G.J. Hoenderop, J. Loffing, P. Meneton, R. J.M. Bindels, M. Paillard, et al. Tissue Kallikrein-Deficient Mice Display a Defect in Renal Tubular Calcium Absorption J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3602 - 3610. [Abstract] [Full Text] [PDF]

				J. Ferreira, A. Beirith, M. A. S. Mori, R. C. Araujo, M. Bader, J. B. Pesquero, and J. B. Calixto Reduced Nerve Injury-Induced Neuropathic Pain in Kinin B1 Receptor Knock-Out Mice J. Neurosci., March 2, 2005; 25(9): 2405 - 2412. [Abstract] [Full Text] [PDF]

				L. M. F. Leeb-Lundberg, F. Marceau, W. Muller-Esterl, D. J. Pettibone, and B. L. Zuraw International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences Pharmacol. Rev., March 1, 2005; 57(1): 27 - 77. [Abstract] [Full Text] [PDF]

				G. Morissette, J.-P. Fortin, S. Otis, J. Bouthillier, and F. Marceau A Novel Nonpeptide Antagonist of the Kinin B1 Receptor: Effects at the Rabbit Receptor J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1121 - 1130. [Abstract] [Full Text] [PDF]